Acrivon Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-8.4M | — |
| FY2021 | — | $-23.8M | $99.6M |
| FY2022 | — | $170.5M | $29.5M |
| FY2023 | — | $121.2M | $36.0M |
| FY2024 | — | $176.8M | $39.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $-8.4M | — |
| FY2021 | — | $-23.8M | $99.6M |
| FY2022 | — | $170.5M | $29.5M |
| FY2023 | — | $121.2M | $36.0M |
| FY2024 | — | $176.8M | $39.8M |